机构:[1]Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150001, China[2]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China四川省人民医院四川省肿瘤医院[3]Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China四川省人民医院[4]School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China[5]NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
Through facilitating DNA homologous recombination repair, PPIP5K2 has been proven to be essential for improving colorectal cancer survival in our previous research. However, its function in the tumorigenesis of NSCLC, the most common cancer and the primary cause of cancer-related death globally, is still unknown. Here, we initially discovered that PPIP5K2 had significant effects on proliferation of NSCLC cells through loss- and gain-of-function assays in vitro and in vivo. Moreover, PPIP5K2 is capable of regulating NSCLC cells metastasis in an EMT-dependent manner. In terms of mechanism exploration, we found that PPIP5K2 knockdown can significantly inhibit the phosphorylation of AKT/mTOR signaling pathway, whereas the overexpression of PPIP5K2 resulted in converse effects. By employing AKT signaling related agonists or antagonists, we further demonstrated that PPIP5K2 regulates NSCLC tumorigenesis partly via the AKT/mTOR pathway. In conclusion, PPIP5K2 plays a key oncogenic role in NSCLC by the activation of the AKT/mTOR signaling axis. It is anticipated that targeting PPIP5K2 might emerge as a viable therapeutic approach for NSCLC patients.
基金:
This research was supported by the National Natural Science Foundation of China (grant
number 82203331, 82300137, 92259102); Natural Science Foundation of Chongqing (grant number
CSTB2023NS CQ-MSX0065); Haiyan Fund of Harbin Medical University Cancer Hospital (Grant
No. JJZD2022–02); Beijing Medical Award Foundation (Grant No. YXJL-2022-0435-0098) and CSCOHengrui
Tumor Research Fund (Y-HR2020ZD-0361).
第一作者机构:[1]Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150001, China
共同第一作者:
通讯作者:
通讯机构:[1]Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150001, China[5]NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
推荐引用方式(GB/T 7714):
Yang Qi,Cao Chenhui,Wu Binghuo,et al.PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway[J].Cancers.2024,16(3):doi:10.3390/cancers16030590.
APA:
Yang Qi,Cao Chenhui,Wu Binghuo,Yang Haochi,Tan Tian...&Huang Xiaoyi.(2024).PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway.Cancers,16,(3)
MLA:
Yang Qi,et al."PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway".Cancers 16..3(2024)